← Patent-cliff monitor Loss of exclusivity November 2028 latest FDA-listed patent expiry
Company ASTRAZENECA AB
Drug detail Brand name ONGLYZA Active ingredient SAXAGLIPTIN HYDROCHLORIDE Strength EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Dosage form TABLET Route ORAL Modality Small molecule FDA approval July 2009 Marketing status DISCN
Listed patents Patent Expires Type 7951400 November 2028 product
Regulatory exclusivity Code Expires M-14 October 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.